FDA fully approves 'novel' Alzheimer’s disease drug Leqembi.
The medicine will be covered by Medicare. The drug works by reducing amyloid plaques that form in the brain, a defining pathophysiological feature of the disease," the statement added.
The FDA disclosed that patients who take anticoagulant medication, or blood thinners, are at increased risk of hemorrhages with Leqembi.
Leqembi is also only approved for use by Alzheimer's patients in the mild dementia or cognitive impairment stage of the disease.
No comments:
Post a Comment